According to Virttu CEOSteven Powell, there are many benefits to potential partners in joining Virttu REPLICATE Open Innovation Forum: “In recent years we have been approached regularly by research groups interested in investigating the use of SEPREHVIR™ in oncology indications, either as a monotherapy or in combination with other treatment modalities. With interest in oncolytic viruses continuing to grow, establishing a formal collaborative network seemed the most efficient way forward. By joining Virttu REPLICATE, researchers gain access to latest data and insights into the use of oncoviruses and access to SEPREHVIR™ – an engineered herpes simplex virus which is highly lytic, has a broad tissue tropism, replicatesselectively in cancer cells and with safety demonstrated in man. In due course we believe this new and innovative initiative will lead to exciting opportunities to create breakthrough research and combination therapies with real clinical impact. “
www.virttureplicate.co.uk
info@virttureplicate.co.uk
Follow us on Twitter @virttureplicate
Media and Press Enquiries:
Richard Hayhurst Associates
Richard Hayhurst Tel : +44(0) 20 3077 5400
